Aardvark Therapeutics faces securities class action
Rosen Law Firm says a securities class action has been filed over Aardvark Therapeutics, citing allegations tied to the company’s IPO registration statement and ARD-101 disclosures. Investors have until Oct. 13, 2026, to seek lead-plaintiff status.